- This event has passed.
AIMS V DEA: A Webinar & Fundraiser to Allow Psilocybin Therapy for Patients with Advanced Illness
August 4 @ 1:00 pm - 2:00 pm
Medical research demonstrates the powerful therapeutic uses of psilocybin in the treatment of anxiety and depression associated with terminal illness. The state and federal “Right to Try” (RTT) acts are intended to allow terminally ill patients access to drugs still in investigational stages, recognizing that such patients do not have the luxury of time to await the slow process of new drug approval. Psilocybin qualifies as such a drug and all other requirements. DEA has refused to accommodate RTT denying Sunil Aggarwal, MD, PhD, FAAPMR and Seattle’s AIMS Institute any access to psilocybin for therapeutic use with terminally ill patients, resulting in a lawsuit now before the 9th Circuit Court.
This is an opportunity to hear directly from Dr. Aggarwal, MD, PhD, FAAPMR and Petitioners’ Lead Counsel, Kathryn Tucker, JD of Emerge Law Group.
Sunil Aggarwal, MD, PhD, FAAPMR is a Board-Certified Physician in Hospice and Palliative Medicine and Physical Medicine and Rehabilitation and Medical Geographer and serves as the Past Chair of the American Academy of Hospice and Palliative Medicine (AAHPM) Integrative Medicine Special Interest Group and an inaugural member of the Safe Use in Psychedelic-Assisted Therapies Forum. He was recently named as a Top 20 Emerging Leader by the AAHPM. He is an Affiliate Assistant Clinical Professor in Rehabilitation Medicine at the University of Washington School of Medicine, an Affiliate Assistant Professor in the Department of Geography, and an Affiliate Clinical Faculty with Bastyr University. He completed his MD and PhD degrees at the University of Washington and Residency and Fellowship at Virginia Mason Medical Center, NYU Langone Health, and the NIH Clinical Center. He is a Co-Founder, Co-Director and Practitioner at the Advanced Integrative Medical Science (AIMS) Institute in Seattle, a multispecialty teaching clinic and research institute offering cutting edge care in oncology, psychiatry, neurology, rehabilitation, pain, and palliative care. He also serves as an Associate Hospice Medicine Director and On-Call Palliative Physician for MultiCare Health System. He is a co-investigator on the AIMS Cancer Outcomes Study, the AIMS Medical Outcomes Study, and the Canadian Psilocybin Safety Initiative Registry. He has published over three dozen peer-reviewed article and book chapters that have been cited over 800 times per Google Scholar.
Kathryn Tucker, JD is Special Counsel and Co-Chair Psychedelic Practice Group at Emerge Law Group, as well as Past Executive Director of the End of Life Liberty Project, the Disability Rights Legal Center, Legal and Advocacy Director Compassion & Choices. Tucker teaches “Law, Medicine, and Ethics at the End of Life” at leading law schools. She served as campaign counsel for Washington’s first Death with Dignity initiative campaign in 1991, and went on to represent the patient and physician plaintiffs in Glucksberg et al v Washington and Quill et al v New York; she argued Glucksberg in the Supreme Court of the United States. Tucker was part of the team that challenged Attorney General John Ashcroft’s attempt to nullify the Oregon Death with Dignity Act, succeeding in preserving that pioneering law. OR et al v Ashcroft/Gonzales. She represented the patient and physician plaintiffs in Montana to establish the right to choose aid in dying in that state. Baxter et al v Montana. More recently Tucker’s work has involved advocacy to open access to psilocybin therapy as a palliative care tool, including involvement with the successful campaign in Oregon to enact the nation’s first psilocybin therapy law, and in litigation to compel the DEA to allow access under state and federal Right to Try laws(AIMS et al v DEA). She is a founding member of the nascent Psychedelic Bar Association, and a frequent speaker on end of life liberty to audiences of legal, medical and health policy professionals as well as communities interested in understanding the evolving legal landscape governing psychedelic substances.